Trials / Completed
CompletedNCT00143377
Study to Determine The Effectiveness Of Detrusitol In Patients Diagnosed With OAB
A Global Phase IV, Double-Blind, Placebo-Controlled, Randomized Trial To Evaluate The Effectiveness Of Detrusitol Sr 4mg On Patient's Perception Of Bladder Condition (PPBC).
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 600 (planned)
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the effectiveness of Detrusitol (tolterodine tartrate) SR, 4 mg once daily, on patient's perception of the symptoms of overactive bladder and which of these bothersome symptoms are improved with treatment.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | tolterodine SR, overactive bladder |
Timeline
- Start date
- 2004-09-01
- Completion
- 2005-10-01
- First posted
- 2005-09-02
- Last updated
- 2021-01-27
Source: ClinicalTrials.gov record NCT00143377. Inclusion in this directory is not an endorsement.